Gufic Biosciences, a company in the Pharmaceuticals industry, reported revenue of ₹261 crore and net profit of ₹22 crore for the June 2026 quarter.
Gufic Biosciences (NSE: GUFICBIO) closed at ₹418.25 on 20 Nov 2026, up 22.1% over the past year. Its market capitalisation is ₹4,194 crore and it trades at 51.1 times earnings.
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.